Construction of a nomogram model to predict the risk of retinopathy of prematurity reactivate after intravitreal anti-vascular endothelial growth factor therapy: a retrospective study

被引:0
|
作者
Shen, Ziyun [1 ]
Hao, Qingfei [1 ]
Yang, Tiantian [1 ]
Cheng, Xiuyong [1 ]
机构
[1] Zheng Zhou Univ, Affiliated Hosp 1, Dept Neonatol, Zhengzhou, Peoples R China
来源
FRONTIERS IN PEDIATRICS | 2025年 / 12卷
关键词
anti-vascular endothelial growth factor; retinopathy of prematurity; reactivate; nomogram; preterm; BLOOD-TRANSFUSION; BEVACIZUMAB; MANAGEMENT; INFANTS;
D O I
10.3389/fped.2024.1440437
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective To explore the risk factors for the reactivate of retinopathy of prematurity (ROP) after intravitreal injection of anti-vascular endothelial growth factor (VEGF) and to construct a nomogram model to predict the risk of ROP reactivate. Methods A retrospective analysis was conducted on 185 ROP children who underwent anti-VEGF treatment at the First Affiliated Hospital of Zhengzhou University from January 2017 to October 2023. They were randomly divided into a training set (129 cases) and a validation set (56 cases) at a ratio of 7:3. The training set was further divided into a reactivate group (n = 18) and a non-reactivate group (n = 111) based on whether ROP recurred after treatment. Multivariable logistic regression analysis was used to screen for risk factors for ROP reactivate. A nomogram model was constructed using R software and validated using the validation set. The discrimination, calibration, and clinical net benefit of the model were evaluated using the receiver operating characteristic curve (ROC curve), calibration curve, and decision curve analysis, respectively. Results Multivariable logistic regression analysis showed that the number of red blood cell transfusions, use of pulmonary surfactant (PS) 2 times or more, and preoperative fundus hemorrhage were independent risk factors for ROP reactivate (P < 0.05). The area under the ROC curve (AUC) of the training set was 0.810 (95% CI: 0.706-0.914), and that of the validation set was 0.756 (95% CI: 0.639-0.873). The Hosmer-Leme show goodness-of-fit test indicated a good fit of the model (P = 0.31). Calibration curve analysis and decision curve analysis suggested high predictive efficacy and clinical application value of the model. Conclusions The number of red blood cell transfusions, use of PS 2 times or more, and preoperative fundus hemorrhage are independent risk factors for ROP reactivate. The nomogram model constructed based on these factors has high predictive efficacy and clinical application value.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Anti-vascular endothelial growth factor intravitreal therapy for retinopathy of prematurity
    VanderVeen, Deborah K.
    Cataltepe, Sule U.
    SEMINARS IN PERINATOLOGY, 2019, 43 (06) : 375 - 380
  • [2] Persistent Angiographic Abnormalities After Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity
    Shah, Neepa
    Gupta, Mrinali P.
    Chan, R. V. Paul
    JAMA OPHTHALMOLOGY, 2018, 136 (04) : 436 - 437
  • [3] Intravitreal Anti-Vascular Endothelial Growth Factor in Retinopathy of Prematurity: Several Years On
    Lauer, Andreas K.
    ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY, 2014, 3 (06): : 329 - 330
  • [4] Anti-vascular endothelial growth factor and retinopathy of prematurity
    Sears, Jonathan E.
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2008, 92 (11) : 1437 - 1438
  • [5] RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY
    Ling, Kiet-Phang
    Liao, Pei-Ju
    Wang, Nan-Kai
    Chao, An-Ning
    Chen, Kuan-Jen
    Chen, Tun-Lu
    Hwang, Yih-Shiou
    Lai, Chi-Chun
    Wu, Wei-Chi
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2020, 40 (09): : 1793 - 1803
  • [6] The risk factors for reactivation of retinopathy of prematurity (ROP) after intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment
    Choi, Ji Youn
    Hwang, Sungsoon
    Kim, Sang Jin
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
  • [7] Intravitreal Anti-Vascular Endothelial Growth Factor inhibitors in Treatment of Retinopathy of Prematurity: Systematic Review
    Emami-naeini, Parisa
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [8] Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor
    Barry, Gerard P.
    Yu, Yinxi
    Ying, Gui-Shuang
    Tomlinson, Lauren A.
    Lajoie, Juliann
    Fisher, Marilyn
    Binenbaum, Gil
    OPHTHALMOLOGY, 2021, 128 (08) : 1188 - 1196
  • [9] Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity:: A morphologic study
    Kong, Lingkun
    Mintz-Hittner, Helen A.
    Penland, Rebecca L.
    Kretzer, Francis L.
    Chevez-Barrios, Patricia
    ARCHIVES OF OPHTHALMOLOGY, 2008, 126 (08) : 1161 - 1163
  • [10] Visual field after anti-vascular endothelial growth factor therapy and laser treatment for retinopathy of prematurity
    Shumpei Obata
    Riko Matsumoto
    Maki Iwasa
    Masashi Kakinoki
    Osamu Sawada
    Tomoko Sawada
    Yoshitsugu Saishin
    Masahito Ohji
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2023, 261 : 3207 - 3213